Adenosine, adenosine receptors and myocardial protection: An updated overview

Cardiovascular Research

Volumn 52, Issue 1, 2001, Pages 25-39

  Mubagwa, Kanigula ^a   Flameng, Willem ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adenosine; Ion channels; Ischemia; Preconditioning; Receptors; Signal transduction

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 ETHYL 4,5 DIPROPYL 3 (ETHYLSULFANYLCARBONYL) 6 PHENYLPYRIDINE 5 CARBOXYLATE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[1,5 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 ETHYL 4 PROPYL 2 PHENYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 6 N (4 SULFOPHENYL)ADENOSINE; 6 N (5 HYDROXYNORBORNAN 2 YL) 8 (N ISOPROPYL N METHYLAMINO) 9 METHYLADENINE; 6 N CYCLOPENTYLADENOSINE; 6 N IODOBENZYL 5 N METHYLCARBOXAMIDOADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; [2 (3,5 DIMETHOXYPHENYL) 2 (2 METHYLPHENYL)ETHYL]ADENOSINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATE; BW A1433U; CHLOROSTYRYLCAFFEINE; CYCLOHEXYLADENOSINE; ENPROFYLLINE; FREE RADICAL; HEAT SHOCK PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; POTASSIUM CHANNEL; PROTEIN KINASE C; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZM 241365;

APOPTOSIS; CARDIOVASCULAR DISEASE; CELL DAMAGE; CONVALESCENCE; CORONARY ARTERY BYPASS GRAFT; DRUG MECHANISM; ENZYME ACTIVATION; HEART MITOCHONDRION; HEART MUSCLE FIBER MEMBRANE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; SARCOPLASMIC RETICULUM; SIGNAL TRANSDUCTION; TISSUE PRESERVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACTION POTENTIALS; ADENOSINE; ADENOSINE TRIPHOSPHATASES; ANIMALS; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA, HEART; MYOCARDIAL ISCHEMIA; MYOCARDIUM; POTASSIUM CHANNELS; PROTEIN KINASE C; RECEPTORS, PURINERGIC P1; SARCOLEMMA;

EID: 0034846624     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00358-3     Document Type: Review

References (181)

1. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology
2. Autonomic neural control of cardiac function: Modulation by adenosine and adenosine 5′-triphosphate
3. 2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes
4. Role of adenosine in the heart and circulation
5. The anti-inflammatory potential of adenosine in ischemia-reperfusion injury: Established and putative beneficial actions of a retaliatory metabolite
6. Adenosine and cardioprotection in the diseased heart
7. Adenosine and ischemic preconditioning
8. The role of adenosine in preconditioning
9. ATP and adenosine signal transduction
10. Adenosine and cardioprotection during ischaemia and reperfusion - An overview
11. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium
12. Supply-to-demand ratio for oxygen determines formation of adenosine by the heart
13. Recent advances in cardiac adenosine metabolism
14. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release
15. 2 in stimulated rat cardiomyocytes
16. 2, and energy status in working guinea pig hearts
17. Inorganic phosphate as regulator of adenosine formation in isolated guinea pig hearts
18. Nucleoside transport inhibition mediates lidoflazine-induced cardioprotection during intermittent aortic crossclamping
19. Effects of ischemia, preconditioning, and adenosine deaminase inhibition on interstitial adenosine levels and infarct size
20. Extracellular adenosine levels and cellular energy metabolism in ischemically preconditioned rat heart
21. ATP channel opener: Effects on interstitial adenosine in dogs
22. Purine metabolite accumulation during myocardial ischemia: Adenosine pretreatment versus brief ischemia
23. Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: Evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection
24. Adenosine receptor subtypes: Characterization and therapeutic regulation
25. 2B receptors
26. Receptors for purines and pyrimidines
27. Adenosine receptor subtypes in the heart: Therapeutic opportunities and challenges
28. 3 receptors: Pharmacological properties, species differences and receptor functions
29. Tissue distribution of adenosine receptor mRNAs in the rat
30. 2a adenosine receptor gene
31. 2a receptor in adult rat ventricular myocyte
32. Functional and molecular characterization of receptor subtypes mediating coronary microvascular dilation to adenosine
33. 2-adenosine receptor agonists do not alter action potential duration, twitch shortening, or cAMP accumulation in guinea pig, rat, or rabbit isolated ventricular myocytes
34. 2a receptor activation in rat heart
35. 2-adenosine receptor agonist, in the mammalian ventricle
36. 2b receptors in cultured fetal chick heart cells. High- and low-affinity coupling to stimulation of myocyte contractility and cAMP accumulation
37. 1 receptor and G alpha protein coupling in rat ventricular myocardium during aging
38. 1 receptor function in the rat heart
39. 1-adenosine receptor-mediated inhibition of norepinephrine release in the rat heart
40. 2A adenosine receptor mediates coronary vasodilation
41. 2 receptor function in rat ventricular myocytes
42. 2-adenosine receptors in guinea-pig ventricular cardiomyocytes
43. 2-adenosine receptors on ventricular cardiomyocytes
44. Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D
45. 3 adenosine receptor
46. Structure-function analysis of inhibitory adenosine receptor regulation
47. 2 receptor desensitization
48. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by adenosine in the perfused rat heart
49. Antagonism of the positive dromotropic effect of isoproterenol by adenosine: Role of nitric oxide, cGMP-dependent cAMP-phosphodiesterase and protein kinase G
50. 1-adenosine receptor stimulation
51. ATP currents in intact ventricular myocytes: Implications for preconditioning
52. 1 receptor activation
53. Analysis of the negative inotropic effect of acetylcholine on frog atrial fibres
54. 2+ channels
55. 1MF-2 cells
56. 1 adenosine receptor reserve for two actions of adenosine on guinea pig atrial myocytes
57. 2+ paradox-induced changes in heart
58. ATP channels
59. 1-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig
60. Adenosine and preconditioning revisited
61. Ischemic preconditioning does not protect against contractile dysfunction in the presence of residual flow: Studies in the isolated, blood-perfused rat heart
62. Failure of preconditioning to improve postcardioplegia stunning of minimally infarcted hearts
63. Role of adenosine receptors in late preconditioning against myocardial stunning in conscious rabbits
64. The role of adenosine and ATP-sensitive potassium channels in the protection afforded by ischemic preconditioning against the post-ischemic endothelial dysfunction in guinea-pig hearts
65. Improved functional recovery by ischaemic preconditioning is not mediated by adenosine in the globally ischaemic isolated rat heart
66. 2 receptor activation
67. 3 receptors
68. 3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart
69. 3 receptors in mediating physiological or pharmacological protection from ischemic myocardial injury in the rabbit heart
70. 3 receptors mediates preconditioning of isolated cardiac myocytes
71. 1 adenosine receptors mimics ischemic preconditioning
72. 3 receptor
73. 1 receptor agonist GR79236, in an anaesthetized rabbit model of myocardial ischaemia and reperfusion
74. ATP channels
75. 3 receptors in protection of isolated human atrial muscle against simulated ischaemia
76. 3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits
77. 3 receptors increases myocardial resistance to ischemia-reperfusion injury
78. 3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning
79. 3 receptors
80. 2 receptors and cyclic adenosine monophosphate to protective ischemic preconditioning of sinusoidal endothelial cells against storage/reperfusion injury in rat livers
81. 2 receptors
82. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C
83. ATP channel
84. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart: Evidence for involvement of p38 MAPK
85. Ischemic preconditioning: From basic mechanisms to clinical applications
86. Translocation of HSP27 to sarcomere induced by ischemic preconditioning in isolated rat hearts
87. + channel for cardiac protection against ischemic injury is dependent on protein kinase C activity
88. 2+ overload injury in rat myocardium
89. SAPKs regulation of ischemic preconditioning
90. PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in conscious rabbits
91. ATP channel
92. ATP channel in preservation of mitochondrial function
93. Comparison of in vitro preconditioning responses of isolated pig and rabbit cardiomyocytes: Effects of a protein phosphatase inhibitor, fostriecin
94. ATP channel antagonist, 5-hydroxydecanoate, blocks ischemic preconditioning in the rat heart
95. Endogenous adenosine does not activate ATP-sensitive potassium channels in the hypoxic guinea pig ventricle in vivo
96. + channel in the mitochondrial inner membrane
97. ATP channel as a receptor for potassium channel openers
98. Mitochondrial ATP-dependent potassium channels: Novel effectors of cardioprotection?
99. ATP-sensitive potassium channels: A review of their cardioprotective pharmacology
100. ATP channels
101. ATP channels and actin cytoskeleton
102. + channels and myocardial preconditioning
103. ATP channels in preconditioning
104. ATP channels in ischemic cardioprotection
105. Roles of tyrosine kinase and protein kinase C in infarct size limitation by repetitive ischemic preconditioning in the rat
106. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels
107. Preconditioning by mitochondrial ATP-sensitive potassium channel openers: An effective approach for improving the preservation of heart transplants
108. Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: A key step in ischemic preconditioning?
109. 1 receptor activation
110. Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: Support for a mitochondrial role in cardioprotection
111. Effect of anoxic preconditioning on ATP-sensitive potassium channels in guinea-pig ventricular myocytes
112. Ecto-5′-nucleotidase plays a role in the cardioprotective effects of heat shock protein 72 in ischemia-reperfusion injury in rat hearts
113. Effects of preconditioning on myocardial interstitial levels of ATP and its catabolites during regional ischemia and reperfusion in the rat
114. Preconditioning-induced attenuation of purine metabolite accumulation during ischemia: Memory and multiple cycles
115. Ecto-5′-nucleotidase is not required for ischemic preconditioning in rabbit myocardium in situ
116. Cardioprotection with ischemic preconditioning and MLA: Role of adenosine-regulating enzymes?
117. Ischaemic preconditioning of myocardium
118. 1-receptor activation in the rabbit
119. + channels in rabbit heart
120. Delayed ischemic preconditioning is mediated by opening of ATP-sensitive potassium channels in the rabbit heart
121. ATP channel induces early and delayed cardioprotective effect: Role of nitric oxide
122. 1 receptors: Evidence from gene-knockout mice
123. 1 receptor induced delayed preconditioning in rabbits: Induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism
124. ATP
125. Rabbit heart can be 'preconditioned' via transfer of coronary effluent
126. Renal ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial ischemia via adenosine receptors in rabbits: Effects of 'remote preconditioning'
127. Renal ischemia preconditions myocardium: Role of adenosine receptors and ATP-sensitive potassium channels
128. ATP channel enhances adenosine-induced cardioprotection
129. The PKC activator PMA preconditions rabbit heart in the presence of adenosine receptor blockade: Is 5′-nucleotidase important?
130. ATP channel
131. ATP channel elicits late preconditioning against myocardial infarction via protein kinase C signaling pathway
132. Involvement of adenosine receptor, potassium channel and protein kinase C in hypoxic preconditioning of isolated cardiomyocytes of adult rat
133. Suppression of reperfusion arrhythmias by preconditioning is inhibited by an ATP-sensitive potassium channel blocker, 5-hydroxydecanoate, but not by protein kinase C blockers in the rat
134. Activation of ecto-5′-nucleotidase by protein kinase C and its role in ischaemic tolerance in the canine heart
135. Tumor necrosis factor in the heart
136. Adenosine decreases post-ischaemic cardiac TNF-alpha production: Anti-inflammatory implications for preconditioning and transplantation
137. Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production. Potential ultimate effector mechanism of preconditioning
138. Intramyocardial infusion of tool drugs for the study of molecular mechanisms in ischemic preconditioning
139. Preconditioning in cardiomyocytes protects by attenuating oxidant stress at reperfusion
140. Metabolic and antioxidant effects of R(+/-)-N6-(2-phenylisopropyl)-adenosine following regional ischemia and reperfusion in canine myocardium
141. 1 receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase
142. 2+ channels. A possible mechanism of ischemic preconditioning
143. 2+ release in rat heart. Implications for ischemic preconditioning
144. 2+ release in rat heart
145. 1 receptor
146. + exchanger
147. Ischemic preconditioning in human and rat ventricle
148. Preconditioning cultured human pediatric myocytes requires adenosine and protein kinase C
149. Optimal myocardial preconditioning in a human model of ischemia and reperfusion
150. + channel
151. It is time to ask what adenosine can do for cardioprotection
152. Low-dose dipyridamole infusion acutely increases exercise capacity in angina pectoris: A double-blind, placebo controlled crossover stress echocardiographic study
153. Chronic dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury
154. 1-adenosine receptors in embryonic chicken heart
155. 1 receptor
156. 1-adenosine receptor system in the guinea pig atrioventricular node
157. Effect of adjunctive intracoronary adenosine on myocardial ischemia, hemodynamic function and left ventricular performance during percutaneous transluminal coronary angioplasty: Clinical access to ischemic preconditioning?
158. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction
159. Preconditioning of human myocardium with adenosine during coronary angioplasty
160. Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: Impact on hemodynamic function and left ventricular performance
161. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial
162. Is adenosine preconditioning truly cardioprotective in coronary artery bypass surgery?
163. Optimal myocardial preconditioning in humans
164. Myocardial preconditioning using adenosine: Review and clinical experience
165. Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery
166. Adenosine myocardial protection: Preliminary results of a phase II clinical trial
167. Adenosine-enhanced ischemic preconditioning provides enhanced postischemic recovery and limitation of infarct size in the rabbit heart
168. 4A) preservation in hypothermic storage and its relation with mitochondrial ATP-sensitive potassium channels
169. Cellular and molecular therapeutic targets for treatment of contractile dysfunction after cardioplegic arrest
170. 3 pretreatment before cardioplegic arrest attenuates postischemic cardiac dysfunction
171. Adenosine as an antiarrhythmic agent
172. 3 adenosine receptor agonist
173. 3 adenosine receptor activation and its suppression by isoproterenol
174. 1 adenosine receptor antagonists block ischemia-reperfusion injury of the heart
175. 1 adenosine receptors prevents the ischaemia-induced sensitisation of adenylyl cyclase: Evidence for a protein kinase C-mediated pathway
176. Preconditioning: We do not need more experiments, because our current knowledge already permits us to develop pharmacological agents
177. Mechanisms of isoflurane-induced myocardial preconditioning in rabbits
178. Volatile anesthetics protect the ischemic rabbit myocardium from infarction
179. Metabolic and functional effects of carbachol and ischaemic preconditioning in rat isolated heart